Reporter Cell Line for Endogenous FXN Gene Expression Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug discovery platforms for Friedreich's ataxia lack the ability to accurately assess endogenous FXN gene activity in native chromosomal and disease-relevant contexts, limiting the identification of modulators of FXN expression.
Innovation Solution
Development of a reporter cell line with a reporter gene fused to the 3'-end of the endogenous frataxin gene, enabling accurate monitoring of FXN gene expression and identifying PKD inhibitors as potential therapeutic agents for treating Friedreich's ataxia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If artificial intronic sequences with extended GAA tracts or FXN reporter fusions are used in HTS assays, then high-throughput screening capability is achieved, but the ability to assess endogenous FXN gene activity in native chromosomal context is lost
Solution Approach 1:
The patent introduces an intermediary element - a minimal intronic sequence containing a single GAA repeat - that bridges the gap between artificial reporter systems and native chromosomal context. This intermediary allows the endogenous FXN gene to be monitored through a reporter fusion while maintaining its native regulatory environment, thus enabling both high-throughput screening and accurate assessment of endogenous gene activity.
Solution Approach 2:
The invention applies local quality by using a targeted, minimal intronic sequence fusion rather than extensive artificial sequences. The fusion is localized to a specific region (intron 1) and uses only the necessary minimal elements (single GAA repeat) to achieve the desired function, preserving the overall native chromosomal context while enabling reporter-based measurement.
2Reliability
If extensive GAA tract sequences are used in reporter constructs, then FXN gene repression can be modeled, but the native chromatin structure and nuclear organization are disrupted
Solution Approach 1:
The patent extracts only the essential element needed to model FXN repression - a single GAA repeat within a minimal intronic sequence - rather than using extensive GAA tracts. This extraction approach maintains the ability to model gene repression while minimizing disruption to native chromatin structure and nuclear organization.
Solution Approach 2:
The invention changes the parameter of GAA repeat quantity from extensive tracts to a single repeat, and changes the structural parameter from artificial extensive sequences to minimal intronic sequences. These parameter changes maintain the biological function of modeling repression while preserving native chromosomal context.
Data Source
Figure 1
AI summary
The present application provides a screening method for compounds useful for the treatment of Friedreich's ataxia, and a method for the treatment of Friedreich's ataxia.